Department of Pediatrics

SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. In this issue, Hoang et al. (460–475) investigate the use of baricitinib as a therapeutic for SARS-CoV-2 and demonstrate that treatment of SARS-CoV-2-infected rhesus macaques with baricitinib early during infection reduces lung pathology and inflammation.

Operation Warp Speed's Chief Science Advisor visited Emory University and urged Americans to continue enrolling in ongoing COVID-19 vaccine trials. On Thursday, Nov. 12, Dr. Moncef Slaoui, chief scientific adviser for Operation Warp Speed, toured the Emory Children’s Center, where two leading COVID vaccine clinical trials are underway.

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.1 Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious.

Pediatrics News

Loading News...


Loading Events...